Canada markets closed

Eli Lilly and Company (LLY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
245.10+8.38 (+3.54%)
At close: 04:02PM EST
242.01 -3.09 (-1.26%)
After hours: 05:27PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close236.72
Open237.49
Bid240.02 x 1000
Ask245.05 x 1200
Day's Range235.05 - 245.22
52 Week Range178.58 - 283.90
Volume3,068,797
Avg. Volume3,107,506
Market Cap234.461B
Beta (5Y Monthly)0.36
PE Ratio (TTM)37.42
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.92 (1.66%)
Ex-Dividend DateFeb. 14, 2022
1y Target EstN/A
All
News
  • GlobeNewswire

    ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022

    SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2022. “2021 was a year of substantial corporate and clinical accomplishments for ALX Oncology. We initiated numerous clinical trials, including two Phase 2 trials in head and neck squamous cell c

  • GlobeNewswire

    Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform

    - Establishes co-development and co-commercialization agreement on Foghorn’s selective BRM program and an additional undisclosed program - Collaboration includes three additional discovery programs - Foghorn to receive $300 million upfront and an equity investment by Lilly of $80 million at $20 per share INDIANAPOLIS and CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc.

  • CNW Group

    New empagliflozin data shows statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

    Full results from the landmark EMPEROR-Preserved Phase III trial demonstrated that empagliflozin showed a 21 per cent relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure in adults with heart failure with preserved ejection fraction (HFpEF) compared with placebo.2 The benefit was independent of ejection fraction or diabetes status,2 establishing empagliflozin as the first and only treatment to significantly improve outcomes for t